Product Name :
Ginsenoside F1
Description:
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.
CAS:
53963-43-2
Molecular Weight:
638.87
Formula:
C36H62O9
Chemical Name:
(2S,3R,4S,5S,6R)-2-{[(2S)-2-[(1S,3aR,3bR,5S,5aR,7S,9aR,9bR,11R,11aR)-5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-en-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
Smiles :
CC1(C)[C@@H]2[C@@H](O)C[C@]3(C)[C@H](C[C@@H](O)[C@@H]4[C@H](CC[C@@]34C)[C@](C)(CCC=C(C)C)O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@]2(C)CC[C@@H]1O
InChiKey:
XNGXWSFSJIQMNC-FIYORUNESA-N
InChi :
InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,45-31-29(43)28(42)27(41)23(18-37)44-31)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(40)32(3,4)30(33)22(39)17-35(24,34)7/h10,20-31,37-43H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24+,25-,26-,27+,28-,29+,30-,31-,33+,34+,35+,36-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Melittin} site|{Melittin} Phospholipase|{Melittin} Protocol|{Melittin} In Vivo|{Melittin} manufacturer|{Melittin} Cancer}
Shelf Life:
≥12 months if stored properly.{{Dipotassium glycyrrhizinate} MedChemExpress|{Dipotassium glycyrrhizinate} Virus Protease|{Dipotassium glycyrrhizinate} Technical Information|{Dipotassium glycyrrhizinate} References|{Dipotassium glycyrrhizinate} supplier|{Dipotassium glycyrrhizinate} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.|Product information|CAS Number: 53963-43-2|Molecular Weight: 638.PMID:32695810 87|Formula: C36H62O9|Chemical Name: (2S,3R,4S,5S,6R)-2-{[(2S)-2-[(1S,3aR,3bR,5S,5aR,7S,9aR,9bR,11R,11aR)-5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-en-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol|Smiles: CC1(C)[C@@H]2[C@@H](O)C[C@]3(C)[C@H](C[C@@H](O)[C@@H]4[C@H](CC[C@@]34C)[C@](C)(CCC=C(C)C)O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@]2(C)CC[C@@H]1O|InChiKey: XNGXWSFSJIQMNC-FIYORUNESA-N|InChi: InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,45-31-29(43)28(42)27(41)23(18-37)44-31)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(40)32(3,4)30(33)22(39)17-35(24,34)7/h10,20-31,37-43H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24+,25-,26-,27+,28-,29+,30-,31-,33+,34+,35+,36-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (156.53 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Ginsenoside F1 has been shown to flaunt anticancer, anti-aging, and antioxidant effects and has demonstrated competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity. The cell viabilities are 68% at the highest concentration of ginsenoside F1 (200 μM) in MTT assays.|In Vivo:|ApoE-/- mice are fed a high fat diet and orally treated with Ginsenoside F1 (50 mg/kg/day) for 8 weeks. Ginsenoside F1 treated mice significantly reduce the lesion size compared with model group mice.|Products are for research use only. Not for human use.|
